HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'New' GNC Tag Sticks With Turnaround Results Still In 'Early Days'

This article was originally published in The Rose Sheet

Executive Summary

Acting CEO Robert Moran says' GNC's investment in two loyalty programs, store redesigns in pilot locations, opening an Amazon online storefront and training store clerks to help customers pick products is in "still early days … but it looks like we are headed in the right direction."

You may also be interested in...



GNC's New Partner Brings China Access And Funding, Takes Board Seats

As GNC reports substantially trimming its net losses in its 2017 fourth-quarter and full-year results, it announces Harbin Pharmaceutical will invest around $300m in GNC, becoming the single largest shareholder, and the two firms will form a JV for manufacturing, marketing and distributing GNC-branded products in China. With the investment, GNC's board expands from six to 11 members, comprising GNC CEO Ken Martindale, five appointed by Harbin and five by GNC.

GNC Loyalty Program Nears 10M Members, But Fee-Based Tier Still Lags

The nutritional, health and wellness manufacturer and retailer ended Q3 with more than 9m loyalty program members, including around 550,000 in fee-based PRO Access and "millions of members" from GNC's discontinued Gold Card program who had not re-registered.

GNC Names CEO, Wind River Woes: Health And Wellness Industry News

Martindale brings familiarity to GNC helm; and FDA warns Wind River Herbs after no response.

Related Content

Topics

UsernamePublicRestriction

Register

RS121108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel